FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209667002> ?p ?o ?g. }

• W3209667002 endingPage "S400" @default.
• W3209667002 startingPage "S400" @default.
• W3209667002 abstract "Introduction: GALAXI 1 is a phase 2, double-blind, placebo-controlled study of guselkumab (GUS), an IL-23 antagonist, for the treatment of patients (pts) with moderately to severely active Crohn’s disease (CD) who had inadequate response or intolerance to conventional therapies (corticosteroid, immunosuppressant) and/or biologics (TNF antagonist, vedolizumab). Patient-reported outcomes from the Inflammatory Bowel Disease Questionnaire (IBDQ) through Week (Wk) 12 following GUS induction are reported here for the interim analysis population. Methods: Pts with moderate to severe CD (CDAI score 220-450) were randomized 1:1:1:1:1 to GUS 200, 600, or 1200mg IV at Wks 0, 4, 8; ustekinumab (UST) ∼6mg/kg IV at Wk 0 and 90mg SC at Wk 8; or placebo (PBO) IV. The IBDQ is a 32-item questionnaire with 4 dimensions: bowel symptoms, emotional function, systemic symptoms, and social function. IBDQ scores range from 32 to 224 with higher scores indicating better quality of life. IBDQ scores were evaluated at Wk 8 and Wk 12 for change from baseline, IBDQ response (defined as ≥16-point improvement from baseline), and IBDQ remission (defined as IBDQ score ≥170) for the GUS combined and PBO treatment groups. UST was a reference arm. Results: Two hundred fifty pts were evaluated; approximately 50% failed previous biologic therapy. Baseline demographics and disease characteristics were generally similar across treatment groups. However, some differences were observed between the groups, the most notable of which included a slightly lower disease duration in the GUS 1200mg IV group (6.2 yrs) compared with the GUS 200mg IV group (11.7 yrs), and a lower mean baseline IBDQ total score in the PBO group (117.3) compared with the GUS combined and UST groups. IBDQ scores change from baseline at Wk 8 and Wk 12 are presented in Table 1. Mean change from baseline in total IBDQ and each of the 4 IBDQ domains was greater among pts in the combined GUS group compared with the PBO group. The proportion of pts who achieved IBDQ response at Wk 8 and Wk 12 was higher in the combined GUS treatment group compared with PBO (Figure 1). A similar trend was seen for IBDQ remission. Conclusion: In pts with moderately to severely active CD, pts treated with GUS (combined) induction therapy reported greater improvement in IBDQ scores compared with PBO as early as Wk 8. A higher proportion of pts treated with GUS compared with PBO achieved IBDQ response and remission at Wks 8 and 12, and this treatment benefit (as delta) increased from Wk 8 to Wk 12.Table 1.: Change from baseline in IBDQ total and domain scores, at Week 8 and Week 12.Figure 1.: IBDQ Response and IBDQ Remission at Week 8 and Week 12." @default.
• W3209667002 created "2021-11-08" @default.
• W3209667002 creator A5001440423 @default.
• W3209667002 creator A5003040664 @default.
• W3209667002 creator A5008149243 @default.
• W3209667002 creator A5017140014 @default.
• W3209667002 creator A5019068697 @default.
• W3209667002 creator A5023113049 @default.
• W3209667002 creator A5040354010 @default.
• W3209667002 creator A5045988031 @default.
• W3209667002 creator A5049169459 @default.
• W3209667002 creator A5054487413 @default.
• W3209667002 creator A5057899912 @default.
• W3209667002 creator A5066649201 @default.
• W3209667002 creator A5083484317 @default.
• W3209667002 date "2021-10-01" @default.
• W3209667002 modified "2023-10-17" @default.
• W3209667002 title "S857 Patient-Reported Outcomes of Response and Remission Following Guselkumab Induction Treatment as Measured by the Inflammatory Bowel Disease Questionnaire: Results Through Week 12 of the Phase 2 GALAXI 1 Study" @default.
• W3209667002 doi "https://doi.org/10.14309/01.ajg.0000776960.58058.bf" @default.
• W3209667002 hasPublicationYear "2021" @default.
• W3209667002 type Work @default.
• W3209667002 sameAs 3209667002 @default.
• W3209667002 citedByCount "0" @default.
• W3209667002 crossrefType "journal-article" @default.
• W3209667002 hasAuthorship W3209667002A5001440423 @default.
• W3209667002 hasAuthorship W3209667002A5003040664 @default.
• W3209667002 hasAuthorship W3209667002A5008149243 @default.
• W3209667002 hasAuthorship W3209667002A5017140014 @default.
• W3209667002 hasAuthorship W3209667002A5019068697 @default.
• W3209667002 hasAuthorship W3209667002A5023113049 @default.
• W3209667002 hasAuthorship W3209667002A5040354010 @default.
• W3209667002 hasAuthorship W3209667002A5045988031 @default.
• W3209667002 hasAuthorship W3209667002A5049169459 @default.
• W3209667002 hasAuthorship W3209667002A5054487413 @default.
• W3209667002 hasAuthorship W3209667002A5057899912 @default.
• W3209667002 hasAuthorship W3209667002A5066649201 @default.
• W3209667002 hasAuthorship W3209667002A5083484317 @default.
• W3209667002 hasBestOaLocation W32096670021 @default.
• W3209667002 hasConcept C126322002 @default.
• W3209667002 hasConcept C142724271 @default.
• W3209667002 hasConcept C159110408 @default.
• W3209667002 hasConcept C168563851 @default.
• W3209667002 hasConcept C1862650 @default.
• W3209667002 hasConcept C204243189 @default.
• W3209667002 hasConcept C204787440 @default.
• W3209667002 hasConcept C27081682 @default.
• W3209667002 hasConcept C2776207728 @default.
• W3209667002 hasConcept C2778260677 @default.
• W3209667002 hasConcept C2779134260 @default.
• W3209667002 hasConcept C2779280984 @default.
• W3209667002 hasConcept C2779951463 @default.
• W3209667002 hasConcept C2908647359 @default.
• W3209667002 hasConcept C71924100 @default.
• W3209667002 hasConcept C90924648 @default.
• W3209667002 hasConcept C99454951 @default.
• W3209667002 hasConceptScore W3209667002C126322002 @default.
• W3209667002 hasConceptScore W3209667002C142724271 @default.
• W3209667002 hasConceptScore W3209667002C159110408 @default.
• W3209667002 hasConceptScore W3209667002C168563851 @default.
• W3209667002 hasConceptScore W3209667002C1862650 @default.
• W3209667002 hasConceptScore W3209667002C204243189 @default.
• W3209667002 hasConceptScore W3209667002C204787440 @default.
• W3209667002 hasConceptScore W3209667002C27081682 @default.
• W3209667002 hasConceptScore W3209667002C2776207728 @default.
• W3209667002 hasConceptScore W3209667002C2778260677 @default.
• W3209667002 hasConceptScore W3209667002C2779134260 @default.
• W3209667002 hasConceptScore W3209667002C2779280984 @default.
• W3209667002 hasConceptScore W3209667002C2779951463 @default.
• W3209667002 hasConceptScore W3209667002C2908647359 @default.
• W3209667002 hasConceptScore W3209667002C71924100 @default.
• W3209667002 hasConceptScore W3209667002C90924648 @default.
• W3209667002 hasConceptScore W3209667002C99454951 @default.
• W3209667002 hasIssue "1" @default.
• W3209667002 hasLocation W32096670021 @default.
• W3209667002 hasLocation W32096670022 @default.
• W3209667002 hasOpenAccess W3209667002 @default.
• W3209667002 hasPrimaryLocation W32096670021 @default.
• W3209667002 hasRelatedWork W2094293739 @default.
• W3209667002 hasRelatedWork W2105059445 @default.
• W3209667002 hasRelatedWork W2147044496 @default.
• W3209667002 hasRelatedWork W2611796762 @default.
• W3209667002 hasRelatedWork W2794344940 @default.
• W3209667002 hasRelatedWork W2888701558 @default.
• W3209667002 hasRelatedWork W2999398425 @default.
• W3209667002 hasRelatedWork W3135634162 @default.
• W3209667002 hasRelatedWork W4236433139 @default.
• W3209667002 hasRelatedWork W4310184611 @default.
• W3209667002 hasVolume "116" @default.
• W3209667002 isParatext "false" @default.
• W3209667002 isRetracted "false" @default.
• W3209667002 magId "3209667002" @default.
• W3209667002 workType "article" @default.